Independent
Tenure on this board
23.5 yrs
Meeting calendar
AORT · Annual meeting · Tuesday, May 12, 2026
Artivion Inc
9 nominees · 3 ballot items.
Elect nine directors; approve, on an advisory basis, executive compensation (“Say on Pay”); and ratify Ernst & Young LLP as independent registered public accounting firm for fiscal 2026.
Market cap
$1.2B
1Y TSR
-28.1%
Board grade
B
Record date
Mar 16, 2026
Filing
DEF 14A
Meeting concluded · May 12, 2026
Follow how the vote landed and what changed on Artivion Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
Proposals
On the ballot3
- 1
Election of Directors
ManagementBoard: FORElect nine nominees to the Board of Directors to serve until the next annual meeting or until their successors are qualified.
- 2
Advisory Vote on Executive Officer Compensation (Say on Pay
ManagementBoard: FORNon-binding, advisory approval of the compensation paid to the Company’s Named Executive Officers as disclosed in the proxy statement.
More detail
Artivion’s advisory Say-on-Pay proposal requests non-binding shareholder approval of the compensation paid to its Named Executive Officers as disclosed in the proxy statement, including the Compensation Discussion and Analysis, compensation tables, and narrative discussion. Management seeks this annual approval to gauge investor support for its pay programs and to demonstrate accountability; the Compensation Committee uses market benchmarking, performance metrics (constant currency revenue growth and constant currency adjusted EBITDA), and independent consultant advice to design a pay-for-performance mix heavy on long-term equity incentives (RSUs and PSUs) with performance-based annual cash bonuses. The board recommends a FOR vote, noting that in 2025 the incentive metrics were achieved at 118.7% payout, reflecting alignment between pay and company performance, and emphasizing retention, market-competitive positioning, and long-term value creation. Key governance context includes robust stock ownership guidelines, a clawback policy, and independent compensation committee oversight; risks include concentrated pay at the CEO level and reliance on adjusted non-GAAP measures for payouts. The vote is advisory and does not bind the company, but the board will consider shareholder feedback in future compensation decisions.
- 3
Ratification of the Preliminary Approval of Ernst & Young LLP as Independent Registered Public Accounting Firm
ManagementBoard: FORRatify the Audit Committee’s preliminary approval of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
Director elections
Nominees on the ballot9
Independent
Tenure on this board
23.5 yrs
Independent
Tenure on this board
8.1 yrs
Independent
Tenure on this board
9.7 yrs
Independent
Tenure on this board
8.8 yrs
Independent
Tenure on this board
3.8 yrs
Not independent
Tenure on this board
New nominee
Independent
Tenure on this board
14.2 yrs
Independent
Tenure on this board
4.8 yrs
Ownership
Latest 13F quarterTop institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | BlackRock, Inc. | 9.8% | 4,738,840 | $174M |
| 2 | NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | 5.1% | 2,456,146 | $90M |
| 3 | FMR LLC | 5.0% | 2,447,959 | $90M |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 4.0% | 1,952,008 | $71M |
| 5 | MORGAN STANLEY | 3.8% | 1,847,557 | $68M |
| 6 | STATE STREET CORP | 3.5% | 1,682,273 | $62M |
| 7 | PERCEPTIVE ADVISORS LLC | 3.4% | 1,637,290 | $60M |
| 8 | BlackRock, Inc. | 2.6% | 1,243,635 | $46M |
| 9 | Juniper Investment Company, LLC | 2.4% | 1,189,136 | $44M |
| 10 | Conestoga Capital Advisors, LLC | 2.4% | 1,175,410 | $43M |
Peers
Nearest market capOther Healthcare sector meetings6
Upcoming shareholder meetings at Artivion Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Avanos Medical IncAVNS
Special meeting·Jul 22, 2026·$1.2B
Aura Biosciences IncAURA
Special meeting·Aug 5, 2026·$707M
Trulieve Cannabis CorpTRLV
Special meeting·Aug 5, 2026·$1.7B
Cross Country Healthcare IncCCRN
Special meeting·Jul 16, 2026·$427M
Anaptysbio IncANAB
Annual meeting·Aug 11, 2026·$1.9B
Seer IncSEER
Annual meeting·Jul 28, 2026·$119M
Reference
Frequently asked questions
- When is the Artivion Inc 2026 annual meeting?
- Artivion Inc (AORT) holds its 2026 annual shareholder meeting on Tuesday, May 12, 2026.
- What is the record date for the Artivion Inc 2026 meeting?
- The record date for the Artivion Inc 2026 meeting is Monday, March 16, 2026. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Artivion Inc's 2026 meeting?
- The board is presenting 9 director nominees at the Artivion Inc 2026 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Artivion Inc 2026 meeting?
- Shareholders will vote on 3 proposals at the Artivion Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.